Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
4.420
+0.040 (0.91%)
At close: Mar 20, 2026, 4:00 PM EDT
4.550
+0.130 (2.94%)
After-hours: Mar 20, 2026, 7:59 PM EDT
Grace Therapeutics Employees
Grace Therapeutics had 6 employees as of March 31, 2025. The number of employees increased by 2 or 50.00% compared to the previous year.
Employees
6
Change (1Y)
2
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$996,500
Market Cap
68.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 6 | 2 | 50.00% |
| Mar 31, 2024 | 4 | -28 | -87.50% |
| Mar 31, 2020 | 32 | 4 | 14.29% |
| Mar 31, 2019 | 28 | 17 | 154.55% |
| Feb 29, 2016 | 11 | 4 | 57.14% |
| Feb 28, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 152 |
| XBiotech | 88 |
| Acrivon Therapeutics | 78 |
| InflaRx | 74 |
| PolyPid | 73 |
| BeyondSpring | 40 |
| Gain Therapeutics | 25 |
| iBio, Inc. | 20 |
GRCE News
- 1 day ago - Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences - GlobeNewsWire
- 23 days ago - Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 5 weeks ago - Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 4 months ago - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update - GlobeNewsWire
- 4 months ago - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting - GlobeNewsWire
- 5 months ago - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review - GlobeNewsWire
- 6 months ago - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting - GlobeNewsWire